Richard Mott

Richard Mott is a seasoned professional in the biopharmaceutical sector, currently serving as the Scientific Business Development Director and Head of Scientific Business Development at Peak Proteins since April 2020. Prior experience includes a role as a Technical Lead Research Scientist at Elanco, focusing on downstream process development for veterinary biopharmaceuticals, and a Research Scientist position at Eli Lilly and Company, where responsibilities included technical support for biopharmaceutical API production and upstream process development. Richard began the career as a Senior Research Scientist at AstraZeneca Pharmaceuticals, specializing in protein engineering and molecular biology. Educational qualifications include a 2.1 honors degree in Biochemistry from the University of Bristol and an MSc with Distinction in Renewable Energy from Loughborough University.